Diagnostic Significance of CD20 and FMC7 Expression in B-Cell Disorders

American Journal of Clinical Pathology

Volumn 120, Issue 5, 2003, Pages 754-759

  Delgado, Julio ^b   Matutes, Estella ^a   Morilla, Alison M ^b   Morilla, Ricardo M ^b   Owusu Ankomah, Kwasi A ^b   Rafiq Mohammed, Furheen ^b   Del Giudice, Ilaria ^b   Catovsky, Daniel ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NONE

Author keywords

CD20; Chronic lymphocytic leukemia; CLL; Diagnosis; FMC7; Lymphomas; Scoring

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FMC7; UNCLASSIFIED DRUG;

ACCURACY; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CELL SUSPENSION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SCORING SYSTEM;

EID: 0242363627     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/FNGCYEMJE3MAE5L2     Document Type: Article

References (22)

1. Zola H, Neoh SH, Potter A, et al. Markers of differentiated B cell leukaemia: CD22 and FMC7 react with different molecules. Dis Markers. 1987;5:227-235.
2. Sanchez ML, Almeida J, Vidriales B, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia. 2002;16:1460-1469.
3. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645.
4. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia. 1996;10:877-895.
5. Moreau EJ, Matutes E, A'Hem RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol. 1997;108:378-382.
6. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2000;4:22-47.
7. Loken MR, Shah VO, Dattilio KL, et al. Flow cytometric analysis of human bone marrow, II: normal B-lymphocyte development. Blood. 1987;70:1316-1324.
8. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364-369.
9. Serke S, Schwaner I, Yordanova M, et al. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after Rituxan therapy and transfectant cell analyses. Cytometry. 2001;46:98-104.
10. Hübl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry. 1998;34:71-74.
11. D'hautcourt JL, Isaac J. Mean fluorescence intensity of dual stained cells [letter]. Cytometry. 1999;38:44-45.
12. Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) Cooperative Group. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol. 1989;42:567-584.
13. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
14. Matutes E, Carrara P, Coignet L, et al. FISH analysis for bcl-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukemias. Leukemia. 1999;13:1721-1726.
15. Jain P, Giustolisi GM, Atkinson S, et al. Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry. J Clin Pathol. 2002;55:940-945.
16. Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of hairy cell leukemia (HCL): proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14:57-61.
17. Zomas AP, Matutes E, Morilla R, et al. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia. 1996;10:1966-1970.
18. Cabezudo E, Carrara P, Morilla R, et al. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica. 1999;84:413-418.
19. Almasri NM, Duque RE, Iturraspe J, et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992;40:259-263.
20. Tefferi A, Bartholmai BJ, Witzig TE, et al. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 1996;106:457-461.
21. Roxburgh AE. Oligosaccharide components of surface glycoproteins from leukemic lymphocytes of chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Leuk Res. 1988;12:95-102.
22. Prystas EM, Parker CJ, Holguin MH, et al. Aberrant glycosylation of L-selectin on the lymphocytes of chronic lymphocytic leukemia. Leukemia. 1993;7:1355-1362.